Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients
Treatment-emergent adverse events will be assessed by frequency and severity across multiple dose levels.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Headquarters of Asahi Kasei Corporation in
“BK virus reactivation, while relatively harmless in immunocompetent people, remains a major complication for kidney transplant recipients, as reactivation of the virus can lead to graft dysfunction and BK nephropathy,” said Carl Kraus, MD, Chief Medical Officer of Asahi Kasei Therapeutics. “For transplant patients and their families, this means a high risk of losing the transplanted kidney. Following encouraging Phase 1 data in healthy volunteers, dosing the first patient in this study represents an important step toward developing a targeted antiviral therapy for a community with no approved treatment options. Our goal is to help protect transplanted organs and improve long-term outcomes for these patients.”
The randomized, double-blind, placebo-controlled Phase 2a trial is part of a Phase 2/3 program designed to evaluate safety, tolerability, and pharmacokinetic profile in adult patients with BKV infection after kidney transplantation across multiple dose levels as assessed by frequency and severity of treatment-emergent adverse events (TEAEs). Progression into Phase 2a is supported by favorable Phase 1 safety, tolerability, and pharmacokinetic data.
About BKV
BKV is a ubiquitous human polyomavirus that is typically acquired in early childhood and persists lifelong without symptoms in more than
About AIC468
AIC468 is an antiviral antisense oligonucleotide (ASO) in clinical development for the treatment of BK virus replication in kidney transplant recipients. The candidate inhibits viral replication in infected cells by modulating splicing of the BKV early coding pre‑mRNA, thereby preventing formation of the mRNA encoding the essential BKV master regulator protein, large T antigen. This innovative approach has already demonstrated potent antiviral activity along with a favorable pharmacokinetic and safety profile in preclinical studies and in a Phase 1 clinical trial in healthy volunteers.
About Asahi Kasei Therapeutics
Asahi Kasei Therapeutics is the global specialty pharmaceutical business of
About Asahi Kasei
Asahi Kasei is a diversified global company that contributes to life and living for people around the world. Since its foundation in 1922, with businesses in ammonia and cellulose fiber, Asahi Kasei has consistently grown through proactive portfolio transformation to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to sustainability by providing solutions to the world’s challenges across its three business sectors: Healthcare, Homes, and Material. For more information, visit https://www.asahi-kasei.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261008761302/en/
Asahi Kasei Therapeutics
Anna Michaels
Director, Corporate Communications
media@aktx.com
Asahi Kasei Corporation
Christian Okeefe
christian.okeefe@ak-america.com
Source: Asahi Kasei